endrainc.com (NDRA): תחזית צמיחת רווח נקי למניה לשנה הבאה

The forward net income growth rate for ENDRA Life Sciences (NDRA) has reached a value where the parameter mark equals 0.00. This trend is supported by the development of the TAEUS system, an affordable MRI analogue for diagnosing liver steatosis. The business relies on scalable software and sensors, eliminating the need for manufacturing plant expenditures. ENDRA Life Sciences (NDRA) is currently revising clinical protocols to bring the equipment into compliance with US regulatory standards.

This indicator assesses the expected earnings per share (EPS) dynamics for the coming year by measuring the gap between current performance and analyst consensus forecasts. By analyzing the trend of EPS growth projections, an investor can gauge the probability of commercial success for ENDRA Life Sciences (NDRA), which currently depends not on general economic conditions, but on obtaining insurance reimbursement codes for TAEUS systems.